Histology-Agnostic Biomarkers in GI Malignancies

Download this slideset for expert perspectives on best practices in testing for MSI/MMR, TMB, PD-L1, and NTRK fusions and using immune checkpoint and TRK inhibitors for patients with GI cancers.
John L. Marshall, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 5.78 MB
Released: July 15, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@clinicaloptions.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Daiichi Sankyo, Inc.
Merck Sharp & Dohme Corp.

Related Content

Video of a live Clinical Care Options (CCO) webinar on immune checkpoint inhibitors for HCC and other hepatobiliary cancers

Lipika Goyal, MD R. Kate Kelley, MD Amit G. Singal, MD, MS Physicians: maximum of 1.5 AMA PRA Category 1 Credits Released: July 27, 2021 Expired: July 26, 2022

Expert review of key data in GI cancers from the 2021 ASCO annual meeting, from Clinical Care Options (CCO)

Manish A. Shah, MD Physicians: maximum of 0.75 AMA PRA Category 1 Credits Released: July 27, 2021 Expired: July 26, 2022

Gain clinical insights quickly with this short slideset from Clinical Care Options (CCO) on key actionable biomarkers for GI cancers

David H. Ilson, MD, PhD John L. Marshall, MD Eric Van Cutsem, MD, PhD Released: July 23, 2021

Interactive algorithm tool with NCCN Guidelines® recommendations for Management of Immune Checkpoint Inhibitor–Related Toxicities v3.2021, from CCO

Released: July 22, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue